Trial · NCT00948389
Results by group158
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 158
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2 | Deaths within 30 days of Tx Discontinuation | 1 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2 | Deaths within 30 days of Tx Discontinuation | 0 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs | Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2 | Deaths within 30 days of Tx Discontinuation | 1 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs | Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2 | Deaths within 30 days of Tx Discontinuation | 0 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs | Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2 | Deaths within 30 days of Tx Discontinuation | 0 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2 | Tx-R Deaths within 30 days of Tx Discontinuation | 0 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2 | Tx-R Deaths within 30 days of Tx Discontinuation | 0 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs | Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2 | Tx-R Deaths within 30 days of Tx Discontinuation | 0 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs | Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2 | Tx-R Deaths within 30 days of Tx Discontinuation | 0 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs | Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2 | Tx-R Deaths within 30 days of Tx Discontinuation | 0 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2 | At Least 1 SAE | 5 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2 | At Least 1 SAE | 1 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs | Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2 | At Least 1 SAE | 4 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs | Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2 | At Least 1 SAE | 4 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs | Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2 | At Least 1 SAE | 0 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2 | At Least 1 Tx-R SAE | 4 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs | Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2 | At Least 1 Tx-R SAE | 0 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs | Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2 | At Least 1 Tx-R SAE | 1 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs | Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2 | At Least 1 Tx-R SAE | 1 | participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs | Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2 | At Least 1 Tx-R SAE | 0 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00948389/results